Kaly-normin

General characteristics. Structure:

Active agent
potassium chloride 1000, 00 (that corresponds to the maintenance of K+524,44 of mg (13,3 asking)
Excipients
Silicon dioxide colloid
anhydrous (Aerosil 200) 10,00
Polyvinylbutyral
(Movital B 30T) 57,50
Cetyl alcohol 17,00
Magnesium stearate 1,00
Talc 8,00

Description. Disk-shaped tablets of white color slightly convex on both sides with the marble drawing, with bitterish taste, inodorous. Color of a tablet on a break – white.

Pharmacological properties:

Pharmacodynamics. The drug containing a macrocell potassium fills shortage of potassium. Potassium reduces excitability and conductivity in a myocardium, weakens toxic effect of cardiac glycosides, without influencing their positive ionotropny action.
In small doses of K+ expands coronary vessels, in big - narrows. Participates in process of carrying out nervous impulses. Activates many cytoplasmatic enzymes, regulates the intracellular osmotic pressure, protein synthesis, transport of amino acids. Improves reduction of skeletal muscles at muscular dystrophy, a myasthenia.

Pharmacokinetics. After intake easily and practically in any quantity it is passively absorbed (absorption - 70%) since its concentration (as food, so released from a dosage form) is higher in a gleam of a small bowel, than in blood. From tablets ретард it is gradually and slowly released throughout a GIT. In an ileal and large intestine of K+ it is allocated in a gut gleam by the principle of the interfaced exchange with Na + and allocated with bile (10%). Distribution of K+ in an organism continues about 8 h from the moment of reception: An elimination half-life in an absorption phase - 1.31 h; release time from tablets ретард - 6 h.

Indications to use:

Prevention and treatment of a hypopotassemia of various genesis including
- the caused various states and diseases (vomiting, diarrhea)
- the caused medicinal therapy (diuretics, glucocorticosteroids, cardiac glycosides).

Route of administration and doses:

The dose of drug is established individually, depending on a disease and potassium concentration in a blood plasma. Appoint on 1 – 2 g/days (at the rate on potassium chloride) if necessary increase a dose to 6 g/days.

Features of use:

During treatment it is necessary to control the maintenance of K+ in blood serum, an ECG, at treatment of a hypopotassemia - control of the acid-base state (ABS). Safety and efficiency of use of potassium of chloride for children are not established. In need of use at pregnancy it is necessary to compare the expected advantage for mother and potential risk for a fruit. In the period of a lactation it is necessary to resolve an issue of the breastfeeding termination. The diet with high content of sodium of chloride increases removal of K+ from an organism. It is necessary to consider that the hyperpotassemia leading to a lethal outcome can quickly develop and proceed asymptomatically.

Side effects:

From a GIT: nausea, vomiting, diarrhea, meteorism, abdominal pains, ulcerations of a mucous membrane of a GIT, gastrointestinal bleedings, perforation and impassability of intestines. From a nervous system: paresthesias, muscular weakness, confusion of consciousness. From cardiovascular system: decrease in the ABP, arrhythmia, heart block, cardiac standstill.
Others: hyperpotassemia, allergic reactions.

Interaction with other medicines:

Kaliysberegayushchy diuretics, potassium drugs, APF, NPVP inhibitors increase risk of development of a hyperpotassemia. Reduces side effect of cardiac glycosides. Strengthens effect of quinidine, side effect of Disopyramidum.

Contraindications:

Hypersensitivity to drug, a hyperpotassemia, full AV blockade, adrenal insufficiency, a chronic renal failure, the accompanying therapy by kaliysberegayushchy diuretics, metabolic disturbances (acidosis, a hypovolemia with a hyponatremia), GIT erosive cankers, pregnancy, the lactation period. Age up to 18 years.

Overdose:

Symptoms: hyperpotassemia (muscular hypotone, paresthesias, delay of AV of conductivity, arrhythmia, cardiac standstill). Precursory clinical signs of a hyperpotassemia usually appear at concentration of K+ in serum more than 6 ¼Ý¬ó/l: T tooth point, broadening of the QRS complex.
Heavier symptoms hyperpotassemiasof - paralysis of muscles and a cardiac standstill - develop at concentration of K+ 9-10 ¼Ý¬ó/l. Treatment: inside or in/in - chloride sodium solution; if necessary - a hemodialysis and peritoneal dialysis.

Storage conditions:

In the place, dry and unavailable to children, at a temperature from 15 to 30ºС. Period of validity 3 years. Not to use after the term specified on packaging.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in the blister.
3 blisters (30 tablets) place in a cardboard box together with the application instruction.